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In the present study, we have examined the kinetics and magnitude of expression of the CD28 and CD152molecules on
unstimulated and anti-CD3þrIL-2-stimulated peripheral blood CD4þ and CD8þ T cells in patients with chronic lymphocytic
leukaemia (B-CLL) and controls. The mean percentages of both CD3þ/CD4þ/CD28þ and CD3þ/CD8þ/CD28þ cells were
significantly lower in B-CLL than in controls before culture, decreased rapidly, reaching their lowest levels between 24 and 48h, and
returned to basal levels after 72h of culture. In controls, the lowest proportions of CD3þ/CD4þ/CD28þ and CD3þ/CD8þ/
CD28þ cells were found after 24h and returned to prestimulation levels after 48h of stimulation. We observed significantly higher
proportions of unstimulated CD3þ/CD4þ/CD152þ and CD3þ/CD8þ/CD152þ cells in B-CLL patients than in controls. The
highest percentages of CD3þ/CD4þ/CD152þ and CD3þ/CD8þ/CD152þ cells were observed in controls after 72h, and in
B-CLL patients after 24h, and remained statistically higher after 48, 72 and 96h of stimulation. CD152molecule expression returned
to prestimulation levels after 96h of culture in controls, and after 120h in B-CLL patients. The abnormal kinetics and levels of CD28
and CD152 expression on T cells in B-CLL may lead to a state of hyporesponsiveness or anergy and could be one of the mechanisms
of immune deficiency in this disease.
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B-cell chronic lymphocytic leukaemia (B-CLL) is the most frequent
form of adult leukaemia in the Western world, where it accounts
for about 25% of all leukaemias. In addition to the accumulation
and clonal expansion of malignant B cells, several abnormalities
have been demonstrated within the non-malignant T-cell popula-
tion. The nature and the level of T-cell immune deficiency in B-
CLL are the object of intense investigations. Recently, there has
been a growing appreciation of the importance of the costimula-
tory and inhibitory regulation pathways in normal and disease-
related cellular immune function.
The effective activation of naive T lymphocytes requires the
generation of a specialised contact area between the T cell and the
antigen-presenting cells (APCs) known as the immunologic
synapse (Dustin and Cooper, 2000). This area of interaction is
generated by the aggregation of different specialised receptors and
signalling molecules, called supramolecular activation clusters.
The differentiation and expansion of a T cell depends upon two
signals: an antigen-specific interaction between the T–cell receptor
(TCR) and the specific peptide embedded in major histocompat-
ibility complex (MHC) molecules displayed on the surface of the
APC, and an antigen-nonspecific interaction between a costimu-
latory receptor and its ligand. CD28 is the primary T-cell
costimulatory molecule, which is expressed constitutively on
almost all CD4þ T cells and on about 50% of CD8þ T cells.
Upon interaction with the ligands B.7-1 (CD80) and/or B.7-2
(CD86), CD28 transduces a signal that enhances T-cell prolifera-
tion and cytokine secretion and sustains T-cell response (reviewed
in Bocko et al, 2002). In the absence of an appropriate
costimulation, TCR occupancy alone can lead to T-cell unrespon-
siveness or clonal anergy, in which T cells are unable to proliferate
or secrete cytokines in response to a secondary stimulation
(Schwartz, 1996). Consistent with this, CD28-negative transgenic
mice exhibit profound defects in mitogenic responses (Shahinian
et al, 1993), and germinal centres are not formed in response to
immunisation (Ferguson et al, 1996).
Conversely, the CD28 homologue CD152 (CTLA-4: cytotoxic T-
lymphocyte-associated antigen-4), which is transiently expressed
on activated T cells, reaching its highest level after 48–72h of
stimulation (Walunas et al, 1994; Kosmaczewska et al, 2002), plays
an inhibitory role in regulating T-cell activation. The expression of
CD152 within T-cell population is restricted to the subset of T cells
that also express CD28 on the cell surface (Lindsten et al, 1993).
CD152 binds the same ligands like CD28, but has an affinity 10–
50-fold higher than the CD28 receptor for B.7-1 (CD80) and B.7-2
(CD86) molecules (Linsley et al, 1994). CD152 mRNA and protein
synthesis is induced by the ligation of CD28 with its ligands
(Lindsten et al, 1993). CD152 engagement inhibits the induction of
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sthe IL-2 receptor alpha chain (CD25), CD69molecule expression,
CD3/CD28-induced IL-2 mRNA accumulation, and secretion of IL-
2 (Krummel and Allison, 1996; Blair et al, 1998). CD152 ligation
also augments the production of transforming growth factor beta
(TGF-beta) (Chen et al, 1998). Mice lacking CD152 as a result of
targeted gene disruption develop a fatal spontaneous lymphopro-
liferative disease with massive lymphocyte infiltrates in many
organs (Waterhouse et al, 1995; Tivol et al, 1997).
The outcome of an immune response involves a balance between
CD28–mediated T-cell activation and CD152-mediated inhibition.
Little is known about CD28 and CD152 expression on peripheral
blood (PB) T cells in patients with B-CLL. To the best of our
knowledge, only three papers have been published on the
expression of these molecules in B-CLL patients so far (Rossi
et al, 1996; Van den Hove et al, 1998; Scrivener et al, 2001). Our
study was designed to evaluate the kinetics and expression of CD28
and CD152 on unstimulated and anti–CD3þrIL-2-stimulated
CD4þ and CD8þ T lymphocytes from B-CLL patients.
MATERIALS AND METHODS
Patients
Samples from 33 untreated patients aged 33–80 years (mean: 64.
6710.5years) fulfilling the morphologic and immunophenotypic
criteria for the diagnosis of B-CLL were studied. Patients were
graded according to Rai’s staging system as at stages III (17 cases)
and IV (16 cases). The control samples consisted of PB from 25
age- and sex-matched healthy individuals.
The study was approved by the local research ethics committee.
Isolation of peripheral blood mononuclear cells and
culture conditions
Peripheral blood mononuclear cells (PBMCs) were separated from
freshly drawn heparinised peripheral venous blood of the B-CLL
patients and healthy donors by buoyant density gradient
centrifugation on Lymphoflot (Biotest AG, Germany) and washed
three times in 0.9% saline. Peripheral blood mononuclear cells
were suspended at 1 10
6PBMCsml
 1 in RPMI 1640 medium
(Gibko, Paisley, UK) supplemented with 10% foetal calf serum
(Flow Labs, UK), L-glutamine and 50mgml
 1 gentamycin (Gibko),
and cultured with 5ngml
 1 of anti-CD3 monoclonal antibodies
(MoAbs) (Ortho, Neckargemund, Germany) and 500Uml
 1 of rIL-
2 (Eurocetus, Amsterdam, The Netherlands). In our model, rIL-2
served as a second signal to induce optimal immune response.
Control cultures without stimulants were included in each
experiment. The cultures were incubated at 371C in a humidified
atmosphere containing 5% CO2 for 24, 48, 72, 96 and 120h.
Flow cytometric analysis
All experiments on the fresh and cultured cells were carried out by
triple labelling with anti-CD152 (CTLA-4)/RPE (PharMingen,
Becton Dickinson Company, San Diego, CA, USA), anti-CD3/
PerCP (Becton Dickinson, San Jose, CA, USA), anti-CD4/FITC
(Becton Dickinson, San Jose, CA, USA), anti-CD8/FITC (Becton
Dickinson, San Jose, CA, USA), anti-CD28/FITC (Serotec, UK),
anti–CD4/RPE (Becton Dickinson, San Jose, CA, USA) and anti-
CD8/RPE (Becton Dickinson, San Jose, CA, USA) MoAbs.
Briefly, the cells were incubated for 30min at 41C with the
antibodies described above, and excess, unbound antibodies were
removed by two washes with PBS containing 0.5% Tween-20.
Following these washes, the cells were fixed with PBS (without
Ca
2þ and Mg
2þ) and analysed by flow cytometry using a
FACScalibur flow cytometer (Becton Dickinson, Mountain View,
CA, USA). Negative controls were always done by omitting the
MoAb as well as by incubating cells with mouse Ig of the same
isotype as the MoAbs conjugated with fluoresceine or phycoery-
thrin.
The results were expressed as the proportions of CD3þ/CD4þ
and CD3þ/CD8þ cells coexpressing CD28 or CD152 antigen. At
Table 1 The mean percentage of PB CD3+/CD4+/CD28+ and CD3+/CD8+/CD28+ cells before and after 24, 48, 72 and 96h of anti-CD3+rIL-2
stimulation in patients with B-CLL and healthy controls
Time (h)
02 44 8 7 2 9 6 P
CD3+/CD4+/CD28+
B-CLL patients (n¼33) 41.5717.1% 20.179.2% 22.179.9% 35.7713.5% 36.2712.6% I:III¼0.001
(I) (III) (V) (VII) (IX) I:V¼0.005
III:V¼NS
V:VII¼0.001
Healthy controls (n¼25) 78.977.6% 57.078.5% 74.776.5% 82.276.0% 82.176.4% II:IV¼0.002
(II) (IV) (VI) (VIII) (X) IV:VI¼0.004
II:VI¼NS
VI:VIII¼NS
P I:II¼0.0002 III:IV¼0.0001 V:VI¼0.0001 VII:VIII¼0.0001 IX:X¼0.0001
CD3+/CD8+/CD28+
B-CLL patients (n¼33) 36.3717.6% 20.3712.2% 25.1718.4% 41.0715.7% 40.2711.1% I:III¼0.04
(I) (III) (V) (VII) (IX) I:V¼0.05
III:V¼NS
V:VII¼0.02
Healthy controls (n¼25) 59.379.8% 42.6711.2% 52.578.3% 54.778.3% 55.077.6% II:IV¼0.04
(II) (IV) (VI) (VIII) (X) IV:VI¼0.05
II:VI¼NS
VI:VIII¼NS
P I:II¼0.005 III:IV¼0.001 V:VI¼0.001 VII:VIII¼0.01 IX:X¼0.01
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sleast 10000 events per sample were analysed in triple staining
analysis. The CellQuest program was used for statistical analysis of
the acquired data.
Statistical analysis
Statistical analysis was performed using Mann–Whitney U-test
and ANOVA test for repeated measurements. Differences were
considered as statistically significant when the P-value was p0.05.
Summary statistics are given as the mean 7s.d.
RESULTS
The level and kinetics pattern of CD28 expression on
CD3þ/CD4þ and CD3þ/CD8þ T cells in B-CLL patients
and controls
The mean percentage of CD3þ/CD4þ cells coexpressing CD28
was significantly lower in the B-CLL patients than in the controls
before stimulation (P¼0.0002) and after 24h (P¼0.0001), 48h
(P¼0.0001), 72h (P¼0.0001) and 96h (P¼0.0001) of ex vivo
stimulation (Table 1). The mean percentage of CD3þ/CD8þ/
CD28þ cells was also significantly lower in B-CLL patients than in
controls before stimulation (P¼0.005), and after 24h (P¼0.001),
48h (P¼0.001), 72h (P¼0.01) and 96h (P¼0.01) of stimulation
(Table 1). The lowest proportions of CD3þ/CD4þ/CD28þ and
CD3þ/CD8þ/CD28þ cells in B-CLL patients were observed
between 24 and 48h of stimulation, and returned to basal levels
after 72h of culture. In healthy subjects, the lowest proportions of
CD3þ/CD4þ/CD28þ and CD3þ/CD8þ/CD28þ cells were
observed after 24h and returned to prestimulation levels after
48h (Figure 1).
The mean fluorescence intensity (MFI) of the CD28þ cells, as a
measure of the antigen density on the cell surface, was significantly
lower on CD4þ T cells in B-CLL patients compared with controls
after 48h (P¼0.01) and 72h (P¼0.03) (Table 2), while
significantly lower MFI values of CD28 on CD3þ/CD8þ cells
compared with controls were found only after 72h of stimulation
(P¼0.03) (Table 2).
The level and kinetics pattern of CD152 expression on
CD3þ/CD4þ and CD3þ/CD8þ T cells in B-CLL patients
and controls
The frequency of CD3þ/CD4þ/CD152þ cells was significantly
higher in B-CLL patients than controls on freshly drawn PB cells
(P¼0.001) and after 24h (P¼0.0001), 48h (P¼0.0001), 72h
(P¼0.0005), 96h (P¼0.001) and 120h (P¼0.001) of stimulation
(Table 3).
The mean percentage of CD3þ/CD8þ/CD152þ cells was also
markedly elevated in B-CLL compared with controls before
stimulation (P¼0.0001) and after 24h (P¼0.0005), 48h
(P¼0.0003), 72h (P¼0.02), 96h (P¼0.0001) and 120h
(P¼0.0001) of stimulation (Table 3).
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Figure 1 The mean percentage of PB CD3þ/CD4þ/CD28þ cells
(A) and CD3þ/CD8þ/CD28þ cells (B) before and after ex vivo 24, 48,
72 and 96h of anti–CD3þrIL-2 stimulation in patients with B-CLL and
normal subjects.
Table 2 MFI values of CD28 on PB CD3+/CD4+ cells and CD3+/CD8+ cells, expressed in arbitrary units (AU), before and after 24, 48, 72 and 96h of
anti-CD3+rIL-2 stimulation in patients with B-CLL and healthy controls
MFI of CD28
0h 24h 48h 72h 96h
CD3+/CD4+
B-CLL patients (n¼33) 41.0729.4 39.4714.7 47.4730.0 36.8729.8 49.4733.8
Healthy controls (n¼25) 38.2711.8 47.574.6 65.0717.8 65.3711.8 55.2713.5
P NS NS 0.01 0.03 NS
CD3+/CD8+
B-CLL patients (n¼33) 44.7721.1 45.3718.5 52.0725.0 42.1731.7 48.7732.6
Healthy controls (n¼25) 40.8731.3 53.3728.4 75.5741.1 69.9733.1 59.8737.6
P NS NS NS 0.03 NS
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sIn healthy subjects, the proportions of both CD3þ/CD4þ/
CD152þ and CD3þ/CD8þ/CD152þ cells increased gradually,
peaked after 72h after stimulation, and returned to basal levels
after 96h of stimulation. In contrast, in B-CLL patients, the highest
proportion of triple-positive cells was observed after 24h of
stimulation, slowly decreased on subsequent days of stimulation,
and returned to prestimulation levels after 120h of culture
(Figure 2).
In addition to the increased frequency of CD3þ/CD4þ/
CD152þ cells, we also observed significantly higher MFI values
of CD152 on CD3þ/CD4þ in B-CLL patients compared with
controls on unstimulated (P¼0.001) as well as on stimulated cells
after 24, 48, and 72h of culture (P¼0.04, 0.01 and 0.03,
respectively) (Table 4). Similar results were obtained in the
CD3þ/CD8þ subpopulation on unstimulated (P¼0.01) and
stimulated cells 24h (P¼0.05), 48h (P¼0.01) and 72h
(P¼0.05) after stimulation (Table 4).
Comparison between CD28 as well as CD152 expressions
on CD4þ and CD8þ T cells before and after ex vivo
stimulation in healthy donors and B-CLL patients
In the control group, a significantly higher proportion of CD3þ/
CD4þ/CD28þ than CD3þ/CD8þ/CD28þ cells was found
before and after 24, 48, 72 and 96h of stimulation (P¼0.0005,
0.0005, 0.0008, 0.0001 and 0.0001, respectively). Mean fluorescence
intensity values did not differ between the subsets of lymphocytes
studied.
In the case of CD152 molecule expression, markedly higher
proportions of CD3þ/CD8þ/CD152þ than CD3þ/CD4þ/
CD152þ cells after 24 and 48h of stimulation (P¼0.05 and
0.04, respectively) as well as higher MFI values tested at the same
time points (P¼0.01 and 0.04, respectively) were found.
In contrast, in B-CLL patients, there were similar frequencies of
CD3þ/CD4þ/CD28þ and CD3þ/CD8þ/CD28þ cells (Table 1)
as well as CD3þ/CD4þ/CD152þ and CD3þ/CD8þ/CD152þ
cells (Table 3). Similarly, there were no marked differences
between the MFI values of both the CD28þ cells and CD152þ
cells within the subsets of T cells studied in these patients.
DISCUSSION
There are only a few reports regarding CD28 expression on
unstimulated and stimulated T lymphocytes in B-CLL. However,
no data concerning the kinetics pattern of the studied molecules
on the subsets of T cells in B-CLL patients and controls have been
reported so far. Rossi et al (1996) found a significant decrease in
CD28molecules on T cells in 33 patients with B-CLL. Similar
results were obtained by Van den Hove et al (1998) in 12 B-CLL
patients. In a recent study, Scrivener et al (2001) reported a
decreased proportion of CD2þ/CD28þ cells, which did not
change upon 4h of stimulation with OKT3 MoAb in 27 patients
with B-CLL. The same authors also found a complete lack of
CD152 expression on freshly drawn PB T-cells of half of the
patients. The 48h ex vivo stimulation with OKT3 MoAb or PHA
Table 3 The mean percentage of PB CD3+/CD4+/CD152+ cells and CD3+/CD8+/CD152+ cells before and after 24, 48, 72, 96 and 120h of anti-
CD3+rIL-2 stimulation in patients with B-CLL and healthy controls
Time (h)
0 24 48 72 96 120 P
CD3+/CD4+/CD152+
B-CLL patients (n¼33) 11.877.2% 19.8711.0% 19.079.3% 18.278.2% 14.774.0% 9.974.2% I:III¼0.002
(I) (III) (V) (VII) (IX) (XI) I:V¼0.003
III:V¼NS
V:VII¼NS
VII:IX¼0.03
IX:XI¼0.01
Healthy controls (n¼25) 3.070.8% 4.771.0% 7.272.0% 10.472.9% 3.270.5% 2.270.4% II:IV¼0.002
(II) (IV) (VI) (VIII) (X) (XII) IV:VI¼0.001
II:VI¼0.0003
VI:VIII¼0.01
VIII:X¼0.0001
X:XII¼NS
P I:II¼0.001 III:IV¼0.0001 V:VI¼0.0001 VII:VIII¼0.0005 IX:X¼0.001 XI:XII¼0.001
CD3+/CD8+/CD152+
B-CLL patients (n¼33) 12.577.8% 20.0715.0% 20.7710.5% 19.779.4% 17.578.0% 11.575.1% I:III¼0.02
(I) (III) (V) (VII) (IX) (XI) I:V¼0.002
III:V¼NS
V:VII¼NS
VII:IX¼NS
IX:XI¼0.0001
Healthy controls (n¼25) 2.971.3% 6.172.0% 10.073.2% 12.073.9% 3.271.1% 2.070.7% II:IV¼0.008
(II) (IV) (VI) (VIII) (X) (XII) IV:VI¼0.004
II:VI¼0.0001
VI:VIII¼0.05
VIII:X¼0.0001
X:XII¼NS
P I:II¼0.0001 III:IV¼0.0005 V:VI¼0.0003 VII:VIII¼0.02 IX:X¼0.0001 XI:XII¼0.0001
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sincreased the mean proportion of CD2þ/CD152þ from 1.972.7
to 6.875.1%. In the present study, we demonstrated for the first
time abnormal levels and a different kinetics pattern of
costimulatory CD28 and inhibitory CD152molecules expression
on ex vivo-stimulated CD3þ/CD4þ and CD3þ/CD8þ PB T cells
in B-CLL patients compared with healthy controls.
Since an analysis of CD28-positive cells within the CD8
population would be complicated by the fact that the CD8 subset
is comprised of both CD3þ T lymphocytes and CD3  NK cells
(Perussia et al, 1983), we performed our studies on CD4þ and
CD8þ T cells using a triple immunostaining method (a T-cell
marker, T-cell-subset markers, and CD28 or CD152). In B-CLL
patients, the proportions of CD28þ cells within the CD3þ/
CD4þ and CD3þ/CD8þ populations before and during
stimulation were significantly lower at each time point tested,
and more pronounced in CD4þ T cells compared with controls.
After stimulation in the control subjects, we found, similar to other
reports (Linsley et al, 1993), a transient decrease of CD28
expression on both subsets of T cells after 24h, which returned
to the prestimulation level after 48h. In the B-CLL patients, the
lowest proportions of both subsets of CD28-positive T cells were
observed between 24 and 48h and returned to basal levels after
72h of ex vivo stimulation. In addition to the decreased frequency
of CD3þ/CD4þ/CD28þ and CD3þ/CD8þ/CD28þ cells in B-
CLL patients, the MFI of the CD28þ cells, as a measure of the
antigen density on the cell surface, was also lower in patients at 48
and 72h on CD4þ T cells and 72h on CD8þ T cells after
stimulation than in the controls.
The mechanisms underlying the abnormalities in CD28 expres-
sion in B-CLL patients are not fully understood. The CD28mole-
cule is lost by normal lymphocytes after repeated stimulation with
IL-2 in long-term culture (Labalette et al, 1999). Based on the fact
that T lymphocytes from B-CLL patients have a phenotype of
activated cells, that is, HLA-DRþ, CD38þ, CD45ROþ, CD11cþ,
CD69þ, CD71þ, CD40Lþ (Dianzani et al, 1994; Van den Hove
et al, 1998; Scrivener et al, 2001), it can be suggested that the loss
of CD28molecule on T lymphocytes before culture is related to a
prolonged in vivo activation of these cells. Our finding of a
markedly increased expression of the inducible suppressory
CD152molecule on freshly drawn CD4þ and CD8þ T cells in
B-CLL patients strengthens the suggestion that T cells in B-CLL are
in a partial state of activation. The loss of CD28 expression on B-
CLL T cells may be also related to the influence of the elevated
TNF-alpha serum levels produced by neoplastic B lymphocytes
and T cells in patients with B-CLL (Adami et al, 1994; Bojarska-
Junak et al, 2002; Gallego et al, 2003). It has been shown that
exposure of T cells to TNF-alpha leads to the direct repression of
the transcriptional activity of the CD28 gene promoter (Bryl et al,
2001).
The mechanisms leading to the prolonged downregulation of
CD28 expression after ex vivo stimulation in B-CLL patients is
difficult to explain. The changes in CD28 expression kinetics due
to differential dynamics of proliferation of CD28-negative T cells
seem unlikely, since these cells display a poor proliferative
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Figure 2 The mean percentage of PB CD3þ/CD4þ/CD152þ cells
(A) and CD3þ/CD8þ/CD152þ cells (B) before and after ex vivo 24,
48, 72, 96 and 120h of anti–CD3þrIL-2 stimulation in patients with B-
CLL and normal subjects.
Table 4 MFI values of CD152 on PB CD3+/CD4+ cells and CD3+/CD8+ cells, expressed in arbitrary units (AU), before and after 24, 48, 72, 96 and
120h of anti-CD3+rIL-2 stimulation in patients with B-CLL and healthy controls
MFI of CD152
0h 24h 48h 72h 96h 120h
CD3+/CD4+
B-CLL patients (n¼33) 2527124 232773 243775 260792 206749 219774
Healthy controls (n¼25) 167739 172730 154731 189773 164748 172764
P 0.001 0.04 0.01 0.03 NS NS
CD3+/CD8+
B-CLL patients (n¼33) 3027168 3047159 3177129 251777 205779 227758
Healthy controls (n¼25) 165736 223746 198754 198734 202755 180764
P 0.01 0.05 0.01 0.05 NS NS
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scapacity, which cannot be overcome by the addition of exogenous
IL-2 (Azuma et al, 1993). The fact that the reversion of CD28 took
place rapidly (between 24 and 48h of stimulation) favours the
interpretation that in B-CLL patients the prolonged downregula-
tion of the surface CD28molecule may result from enhanced
ligation-stimulated CD28 receptor endocytosis, and/or disturbed
recycling to the cell surface or increased proteolytic intracellular
degradation.
The expression and kinetics pattern of the CD152molecule on
PB CD4þ and CD8þ T cells after stimulation also differed
markedly from that observed in normal subjects. The frequencies
of CD3þ/CD4þ/CD152þ and CD3þ/CD8þ/CD152þ cells
were significantly higher at each time point tested compared with
normal subjects. After stimulation in normal subjects, the highest
proportions of T cells coexpressing CD152molecule were found
after 72h of culture, which is similar to the findings of others
(Walunas et al, 1996) and our own previous report (Kosmaczewska
et al, 2002). In patients with B-CLL, the highest proportions of
CD4þ T cells and CD8þ T cells coexpressing CD152 were
observed after 24h and returned to basal levels after 120h, but
after 96h in controls. The results of our present study showing the
abnormal kinetics and expression of CD28 on T cells in B-CLL may
provide a possible explanation for the observed alterations in
CD152 expression after ex vivo stimulation. It has been established
that the physiological downregulation of CD28 expression at both
the mRNA and protein levels during the first 24h of stimulation
rapidly and strongly enhances transcription of the CTLA-4 gene
(Lindsten et al, 1993; Linsley et al, 1993). We suggest that the
significantly lower CD28 antigen expression on both subsets of
unstimulated T cells and its more profound and long-lasting
downregulation after stimulation compared with normal controls
as observed in our study may deliver a stronger and prolonged
stimulus for CD152 induction and expression on the CD3þ/
CD4þ and CD3þ/CD8þ T-cell subpopulations in B-CLL. Since
CD152 inhibits T-cell responses, increased expression of
CD152molecule on both subsets of T cells may result in an
impairment of T-cell function in patients with B-CLL (Bartik et al,
1998; Lee et al, 1998; Metzler et al, 1999; Carreno et al, 2000;
Frydecka et al, 2003; Wolowiec et al, 2003). This hypothesis was
confirmed by our previously reported results, which showed
strong negative correlations between the proportion of PB CD3þ/
CD152þ cells and proliferative activity, IL-2 and IFN-g produc-
tion in patients with Hodgkin’s disease and healthy subjects
(Kosmaczewska et al, 2002).
In summary, the dysregulated expression and kinetics of the
costimulatory CD28 and downregulatory CD152molecules on PB T
cells of patients with B-CLL may likely have a considerable impact
on the biology of T-cell responses and could be one of the
mechanisms of immune deficiency in this disease (Bartik et al,
1998). Therapeutic manipulations of the B-7:CD28:CD152
costimulatory and inhibitory pathways may provide a potential
avenue for increasing T-cell responses in B-CLL patients.
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